Verona Historical Income Statement
| VRNA Stock | USD 39.90 0.06 0.15% |
Historical analysis of Verona Pharma income statement accounts such as Interest Expense of 2.2 M, Selling General Administrative of 45.9 M, Other Operating Expenses of 71.2 M or Total Operating Expenses of 70.5 M can show how well Verona Pharma PLC performed in making a profits. Evaluating Verona Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Verona Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Verona Pharma PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Verona Pharma PLC is a good buy for the upcoming year.
Verona |
About Verona Income Statement Analysis
Verona Pharma PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Verona Pharma shareholders. The income statement also shows Verona investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Verona Pharma Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Verona Pharma PLC. It is also known as Verona Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Verona Pharma PLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Verona Pharma PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Verona Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Verona Pharma PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Verona Pharma's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 45.9 M, whereas Operating Income is projected to grow to (64.4 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Research Development | 79.4M | 49.3M | 17.3M | 19.8M | Depreciation And Amortization | 629K | 636K | 679.6K | 713.6K |
Verona Pharma income statement Correlations
Click cells to compare fundamentals
Verona Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Verona Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 221.6K | 35K | 340K | 521K | 2.1M | 2.2M | |
| Selling General Administrative | 9.0M | 29.8M | 11.7M | 7.2M | 43.7M | 45.9M | |
| Other Operating Expenses | 53.4M | 66.0M | 97.7M | 66.6M | 67.8M | 71.2M | |
| Operating Income | (53.9M) | (74.3M) | (73.3M) | (66.1M) | (67.8M) | (64.4M) | |
| Ebit | (53.9M) | (48.4M) | (42.8M) | (67.9M) | (53.1M) | (50.5M) | |
| Ebitda | (51.8M) | (47.8M) | (42.2M) | (67.3M) | (52.5M) | (49.8M) | |
| Total Operating Expenses | 53.4M | 66.0M | 97.7M | 66.2M | 67.2M | 70.5M | |
| Income Before Tax | (51.4M) | (65M) | (55.6M) | (68.4M) | (55.2M) | (52.5M) | |
| Total Other Income Expense Net | 2.5M | 6.8M | (1.4M) | 7.3M | 12.6M | 13.2M | |
| Net Income | (41.9M) | (65.1M) | (55.6M) | (68.7M) | (54.4M) | (51.7M) | |
| Depreciation And Amortization | 2.1M | 627.8K | 629K | 636K | 679.6K | 713.6K | |
| Research Development | 43.9M | 44.5M | 79.4M | 49.3M | 17.3M | 19.8M | |
| Income Tax Expense | (9.5M) | 146K | (18K) | 253K | (632.4K) | (664.1K) | |
| Gross Profit | (509.8K) | (627.8K) | 40M | 112K | (679.6K) | (645.6K) | |
| Net Income From Continuing Ops | (31.9M) | (65.1M) | (55.6M) | (68.7M) | (50.7M) | (48.2M) | |
| Net Income Applicable To Common Shares | (40.6M) | (65.1M) | (55.6M) | (68.7M) | (61.8M) | (58.7M) | |
| Tax Provision | (7.3M) | 146K | (18K) | 253K | 555K | 582.8K | |
| Interest Income | 754K | 121K | 14K | 2.8M | 11.3M | 11.9M | |
| Net Interest Income | 585K | 86K | (326K) | 2.3M | 9.7M | 10.2M | |
| Reconciled Depreciation | 660.8K | 623K | 629K | 636K | 620K | 543.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.